Merck Reports $4.24 Billion Net Loss in Q1 2026 Amid Increased R&D Expenses

Merck & Co., Inc. reported a significant decline in its financial performance for the first quarter of 2026, with a net loss of $4.24 billion, compared to a net income of $5.08 billion in the same period last year. This resulted in a basic loss per share of $1.72, a stark contrast to earnings of $2.01 per share in the first quarter of 2025. Total sales for the quarter reached $16.29 billion, marking a 5% increase from $15.53 billion in the prior year, driven primarily by growth in oncology and animal health segments.

The company's financial results were heavily impacted by substantial research and development expenses, which surged to $12.59 billion from $3.62 billion year-over-year. This increase was largely attributed to a $9 billion charge related to the acquisition of Cidara Therapeutics, which was finalized in January 2026. Additionally, restructuring costs rose to $195 million from $69 million, reflecting ongoing efforts to optimize operations and reduce costs. Overall, total costs and expenses for the quarter amounted to $19.82 billion, significantly higher than the $9.63 billion reported in the previous year.

Strategically, Merck has been active in expanding its portfolio through acquisitions. In March 2026, the company announced its intention to acquire Terns Pharmaceuticals for approximately $6.7 billion, which is expected to close in May 2026. This acquisition aims to enhance Merck's oncology pipeline with TERN-701, a promising treatment for chronic myeloid leukemia. The company also completed the acquisition of Cidara Therapeutics, which focuses on developing long-acting antiviral therapies. These acquisitions are part of Merck's broader strategy to bolster its research capabilities and product offerings in high-growth therapeutic areas.

Operationally, Merck's sales performance varied across its product lines. The oncology segment, led by Keytruda, generated $7.91 billion in sales, up from $7.21 billion, while animal health sales increased to $1.79 billion from $1.59 billion. However, vaccine sales, particularly for Gardasil, saw a decline of 19% due to reduced demand and unfavorable purchasing patterns. The company also faced challenges in its diabetes segment, with combined sales of Januvia and Janumet dropping 28% as competitive pressures intensified.

Looking ahead, Merck anticipates continued challenges in the market, particularly due to pricing pressures from government regulations and increased competition. The company is focused on executing its restructuring programs, which are expected to yield significant cost savings by the end of 2027. Despite the current setbacks, Merck remains committed to advancing its pipeline and leveraging its acquisitions to drive future growth.